Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chinese registry of adults with atopic dermatitis receiving abrocitinib
ChiCTR2400086045Phase 4Recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of abrocitinib in atopic dermatitis (AD), sponsored by First Hospital of China Medical University. Primary endpoint: Baseline demographic and clinical characteristics and their changes during follow-up. Started Jun 2024; status: recruiting.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on ChiCTR2400086045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086045.